Stock Events

Stock Events

THX Pharma 

€0
18
+€0+0% Wednesday 16:27

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
1,012,320
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-1.77MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow THXDS.PA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology and has a strong pipeline in neurological disorders, directly competing with Theranexus's focus on the central nervous system.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a significant presence in the neurology space, including treatments for Alzheimer's, which overlaps with Theranexus's therapeutic areas.
Novartis
NVS
Mkt Cap237.61B
Novartis has a broad portfolio in neuroscience, competing in the development of treatments for neurological conditions.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a history of developing drugs for neurological diseases, competing with Theranexus in the neurology market.
Merck
MRK
Mkt Cap214.76B
Merck is involved in neurology and has been focusing on treatments for conditions like Alzheimer's, directly competing with Theranexus's focus areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a growing interest in neuroscience, including R&D in neurodegenerative diseases, making it a competitor to Theranexus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has initiatives in neuroscience, particularly in migraine treatments, which could overlap with Theranexus's therapeutic targets.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical is a key player in the generic and specialty medicine space, including neurology, competing with Theranexus in terms of therapeutic solutions.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a diversified portfolio that includes neuroscience, competing with Theranexus in research and development of neurological treatments.

About

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.
Show more...
CEO
Mr. Mathieu Charvériat
Employees
10
Country
FR
ISIN
FR0014013QO4

Listings

F
DE
3VG.F
PA
FR
ALTHX.PA

0 Comments

Share your thoughts

FAQ

What is THX Pharma stock price today?▼
The current price of THXDS.PA is €0 EUR — it has increased by +0% in the past 24 hours. Watch THX Pharma stock price performance more closely on the chart.
What is THX Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange THX Pharma stocks are traded under the ticker THXDS.PA.
What is THX Pharma revenue for the last year?▼
THX Pharma revenue for the last year amounts to 0 EUR.
What is THX Pharma net income for the last year?▼
THXDS.PA net income for the last year is -1.77M EUR.
How many employees does THX Pharma have?▼
As of April 05, 2026, the company has 10 employees.
In which sector is THX Pharma located?▼
THX Pharma operates in the Health Care sector.
When did THX Pharma complete a stock split?▼
THX Pharma has not had any recent stock splits.
Where is THX Pharma headquartered?▼
THX Pharma is headquartered in Lyon, FR.